Anifrolumab was all-but written off in 2018 after failing the phase 3 TULIP-1 trial, but bounced back with positive data from a second study – TULIP-2 – that has proved sufficient for the FDA ...

AstraZeneca has been dealt a setback in attempts to rebuild its pipeline after anifrolumab lupus drug failed to reduce disease activity in a phase 3 trial. There was no word on whether AZ will ...

Zahi Touma, MD, PhD, from the University Health Network in Toronto, and colleagues examined whether anifrolumab plus SOC is associated with reduced organ damage accumulation compared with SOC only ...

Anifrolumab (brand name Saphnelo) reduced the risk of long-term organ damage progression by about 60% in patients with moderately to severely active lupus, researchers reported in a new study ...

A recent study evaluated the effectiveness of anifrolumab (Saphnelo®) combined with standard of care (SOC) treatments compared to SOC treatment alone in preventing organ damage. Results showed that ...

The likelihood of experiencing an increase in Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index within 208 weeks was lower for patients in the ...

A newer lupus drug can protect patients from long-term organ damage Anifrolumab (Saphnelo) lowered the risk of long-term organ damage progression by about 60% The drug received federal approval in ...

THURSDAY, Feb. 20, 2025 (HealthDay News) -- For patients with moderately to severely active systemic lupus erythematosus (SLE), anifrolumab is associated with less organ damage after 208 weeks ...

Anifrolumab (Saphnelo) lowered the risk of long-term organ damage progression by about 60% The drug received federal approval in 2021 WEDNESDAY, Feb. 19, 2025 (HealthDay News) -- Lupus can do ...

Join the NonStop Local Chord group and always be in the know. Anifrolumab (Saphnelo) lowered the risk of long-term organ damage progression by about 60% The drug received federal approval in 2021 ...